This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

This study has been completed.
Information provided by:
Nuon Therapeutics, Inc. Identifier:
First received: October 6, 2009
Last updated: January 5, 2011
Last verified: January 2011
This is a randomized, double-blind, 3-period crossover phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics (PK) and pharmacodynamics (PD) and to evaluate the effect of febuxostat on tranilast PK and PD as measured by reduction in serum uric acid levels.

Condition Intervention Phase
Gout Hyperuricemia Drug: Tranilast Drug: Febuxostat Drug: Combination - Tranilast and Febuxostat Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Febuxostat Compared With Tranilast Alone and Febuxostat Alone in Healthy Subjects With Hyperuricemia

Resource links provided by NLM:

Further study details as provided by Nuon Therapeutics, Inc.:

Primary Outcome Measures:
  • Mean decrease in serum uric acid levels [ Time Frame: Seven days ]

Secondary Outcome Measures:
  • Analysis of pharmacokinetic parameters (AUC, Cmax) of tranilast, febuxostat and combination [ Time Frame: 7 days ]

Enrollment: 24
Study Start Date: September 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tranilast
Tranilast tablets
Drug: Tranilast
Tranilast tablets, 300 mg, QD
Active Comparator: Febuxostat
Febuxostat tablets
Drug: Febuxostat
Febuxostat Tablets, 40 mg, QD
Other Name: Uloric
Experimental: Combination
Tranilast plus febuxostat
Drug: Combination - Tranilast and Febuxostat
Tranilast, 300 mg QD; Febuxostat, 40 mg QD


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, aged 18 to 70
  • Subjects with hyperuricemia who are otherwise healthy

Exclusion Criteria:

  • Pregnant or nursing
  • Known history of gout
  • Clinically significant infection at Screening
  • Known sensitivity to tranilast or febuxostat
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00995618

United States, Hawaii
Nuon Investigative Site
Honolulu, Hawaii, United States
United States, Indiana
Nuon Investigative Site
Evansville, Indiana, United States
United States, Texas
Nuon Investigative Site
Dallas, Texas, United States
Sponsors and Collaborators
Nuon Therapeutics, Inc.
Study Director: Director, Nuon Clinical Trials Group Nuon Therapeutics, Inc.
  More Information

Responsible Party: Nuon Therapeutics Clinical Trials Contact, Nuon Therapeutics Identifier: NCT00995618     History of Changes
Other Study ID Numbers: A3006GT
Study First Received: October 6, 2009
Last Updated: January 5, 2011

Keywords provided by Nuon Therapeutics, Inc.:

Additional relevant MeSH terms:
Pathologic Processes
Gout Suppressants
Antirheumatic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Platelet Aggregation Inhibitors
Anti-Allergic Agents processed this record on September 21, 2017